Heatwurx (PCSA) Competitors

$2.65 0.00 (0.00%)

Closing price 05/22/2026 04:00 PM Eastern

Extended Trading

$2.57 -0.08 (-3.13%)

As of 05/22/2026 08:00 PM Eastern

PCSA vs. BTAI, SNTI, NNVC, RNTX, and SKYE

Should you buy Heatwurx stock or one of its competitors? MarketBeat compares Heatwurx with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Heatwurx include BioXcel Therapeutics (BTAI), Senti Biosciences (SNTI), NanoViricides (NNVC), Rein Therapeutics (RNTX), and Skye Bioscience (SKYE). These companies are all part of the "pharmaceutical products" industry.

How does Heatwurx compare to BioXcel Therapeutics?

Heatwurx (NASDAQ:PCSA) and BioXcel Therapeutics (NASDAQ:BTAI) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, profitability, institutional ownership, media sentiment, valuation and earnings.

Heatwurx has higher earnings, but lower revenue than BioXcel Therapeutics. Heatwurx is trading at a lower price-to-earnings ratio than BioXcel Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Heatwurx	N/A	N/A	-$13.56M	-$9.29	N/A
BioXcel Therapeutics	$640K	54.52	-$69.90M	-$5.75	N/A

Heatwurx has a net margin of 0.00% compared to BioXcel Therapeutics' net margin of -11,078.53%. BioXcel Therapeutics' return on equity of 0.00% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Heatwurx	N/A	-281.31%	-200.80%
BioXcel Therapeutics	-11,078.53%	N/A	-201.53%

91.9% of Heatwurx shares are owned by institutional investors. Comparatively, 30.7% of BioXcel Therapeutics shares are owned by institutional investors. 2.4% of Heatwurx shares are owned by company insiders. Comparatively, 3.7% of BioXcel Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Heatwurx presently has a consensus price target of $25.00, suggesting a potential upside of 843.40%. BioXcel Therapeutics has a consensus price target of $11.00, suggesting a potential upside of 873.45%. Given BioXcel Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe BioXcel Therapeutics is more favorable than Heatwurx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
BioXcel Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

Heatwurx has a beta of 1.01, indicating that its stock price is 1% more volatile than the broader market. Comparatively, BioXcel Therapeutics has a beta of 0.31, indicating that its stock price is 69% less volatile than the broader market.

In the previous week, BioXcel Therapeutics had 2 more articles in the media than Heatwurx. MarketBeat recorded 6 mentions for BioXcel Therapeutics and 4 mentions for Heatwurx. Heatwurx's average media sentiment score of 1.00 beat BioXcel Therapeutics' score of -0.35 indicating that Heatwurx is being referred to more favorably in the media.

Company	Overall Sentiment
Heatwurx	Positive
BioXcel Therapeutics	Neutral

Summary

BioXcel Therapeutics beats Heatwurx on 9 of the 15 factors compared between the two stocks.

How does Heatwurx compare to Senti Biosciences?

Senti Biosciences (NASDAQ:SNTI) and Heatwurx (NASDAQ:PCSA) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, profitability, risk, media sentiment, dividends and earnings.

Heatwurx has lower revenue, but higher earnings than Senti Biosciences. Senti Biosciences is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Senti Biosciences	$20K	1,537.10	-$61.44M	-$1.92	N/A
Heatwurx	N/A	N/A	-$13.56M	-$9.29	N/A

25.7% of Senti Biosciences shares are owned by institutional investors. Comparatively, 91.9% of Heatwurx shares are owned by institutional investors. 3.1% of Senti Biosciences shares are owned by company insiders. Comparatively, 2.4% of Heatwurx shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, Senti Biosciences had 4 more articles in the media than Heatwurx. MarketBeat recorded 8 mentions for Senti Biosciences and 4 mentions for Heatwurx. Heatwurx's average media sentiment score of 1.00 beat Senti Biosciences' score of -1.00 indicating that Heatwurx is being referred to more favorably in the news media.

Company	Overall Sentiment
Senti Biosciences	Negative
Heatwurx	Positive

Senti Biosciences presently has a consensus target price of $8.75, indicating a potential upside of 786.61%. Heatwurx has a consensus target price of $25.00, indicating a potential upside of 843.40%. Given Heatwurx's higher possible upside, analysts clearly believe Heatwurx is more favorable than Senti Biosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Senti Biosciences	1 Sell rating(s)	0 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.80
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Senti Biosciences has a beta of 2.09, meaning that its share price is 109% more volatile than the broader market. Comparatively, Heatwurx has a beta of 1.01, meaning that its share price is 1% more volatile than the broader market.

Heatwurx's return on equity of -281.31% beat Senti Biosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Senti Biosciences	N/A	-532.05%	-103.35%
Heatwurx	N/A	-281.31%	-200.80%

Summary

Senti Biosciences beats Heatwurx on 9 of the 15 factors compared between the two stocks.

How does Heatwurx compare to NanoViricides?

NanoViricides (NYSE:NNVC) and Heatwurx (NASDAQ:PCSA) are both small-cap medical companies, but which is the better investment? We will compare the two businesses based on the strength of their risk, analyst recommendations, dividends, media sentiment, institutional ownership, earnings, valuation and profitability.

In the previous week, Heatwurx had 2 more articles in the media than NanoViricides. MarketBeat recorded 4 mentions for Heatwurx and 2 mentions for NanoViricides. Heatwurx's average media sentiment score of 1.00 beat NanoViricides' score of 0.12 indicating that Heatwurx is being referred to more favorably in the news media.

Company	Overall Sentiment
NanoViricides	Neutral
Heatwurx	Positive

NanoViricides is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NanoViricides	N/A	N/A	-$8.29M	-$0.43	N/A
Heatwurx	N/A	N/A	-$13.56M	-$9.29	N/A

NanoViricides' return on equity of -87.90% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NanoViricides	N/A	-87.90%	-78.69%
Heatwurx	N/A	-281.31%	-200.80%

NanoViricides has a beta of 1.54, indicating that its share price is 54% more volatile than the broader market. Comparatively, Heatwurx has a beta of 1.01, indicating that its share price is 1% more volatile than the broader market.

10.3% of NanoViricides shares are held by institutional investors. Comparatively, 91.9% of Heatwurx shares are held by institutional investors. 3.6% of NanoViricides shares are held by company insiders. Comparatively, 2.4% of Heatwurx shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Heatwurx has a consensus target price of $25.00, suggesting a potential upside of 843.40%. Given Heatwurx's higher probable upside, analysts plainly believe Heatwurx is more favorable than NanoViricides.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NanoViricides	0 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	3.00
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Summary

NanoViricides beats Heatwurx on 7 of the 12 factors compared between the two stocks.

How does Heatwurx compare to Rein Therapeutics?

Rein Therapeutics (NASDAQ:RNTX) and Heatwurx (NASDAQ:PCSA) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, profitability, analyst recommendations, dividends, institutional ownership, media sentiment, valuation and risk.

90.9% of Rein Therapeutics shares are owned by institutional investors. Comparatively, 91.9% of Heatwurx shares are owned by institutional investors. 5.1% of Rein Therapeutics shares are owned by insiders. Comparatively, 2.4% of Heatwurx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Heatwurx had 4 more articles in the media than Rein Therapeutics. MarketBeat recorded 4 mentions for Heatwurx and 0 mentions for Rein Therapeutics. Heatwurx's average media sentiment score of 1.00 beat Rein Therapeutics' score of 0.00 indicating that Heatwurx is being referred to more favorably in the news media.

Company	Overall Sentiment
Rein Therapeutics	Neutral
Heatwurx	Positive

Rein Therapeutics presently has a consensus price target of $8.00, suggesting a potential upside of 676.70%. Heatwurx has a consensus price target of $25.00, suggesting a potential upside of 843.40%. Given Heatwurx's higher possible upside, analysts plainly believe Heatwurx is more favorable than Rein Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Rein Therapeutics	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Rein Therapeutics is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Rein Therapeutics	N/A	N/A	-$49.87M	-$1.90	N/A
Heatwurx	N/A	N/A	-$13.56M	-$9.29	N/A

Rein Therapeutics has a beta of 1.42, suggesting that its stock price is 42% more volatile than the broader market. Comparatively, Heatwurx has a beta of 1.01, suggesting that its stock price is 1% more volatile than the broader market.

Heatwurx's return on equity of -281.31% beat Rein Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Rein Therapeutics	N/A	-510.35%	-68.14%
Heatwurx	N/A	-281.31%	-200.80%

Summary

Heatwurx beats Rein Therapeutics on 7 of the 11 factors compared between the two stocks.

How does Heatwurx compare to Skye Bioscience?

Skye Bioscience (NASDAQ:SKYE) and Heatwurx (NASDAQ:PCSA) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, valuation, dividends, media sentiment, profitability, analyst recommendations, institutional ownership and risk.

21.1% of Skye Bioscience shares are held by institutional investors. Comparatively, 91.9% of Heatwurx shares are held by institutional investors. 6.2% of Skye Bioscience shares are held by company insiders. Comparatively, 2.4% of Heatwurx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Skye Bioscience currently has a consensus target price of $9.80, suggesting a potential upside of 1,081.72%. Heatwurx has a consensus target price of $25.00, suggesting a potential upside of 843.40%. Given Skye Bioscience's stronger consensus rating and higher possible upside, research analysts clearly believe Skye Bioscience is more favorable than Heatwurx.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Skye Bioscience	1 Sell rating(s)	2 Hold rating(s)	3 Buy rating(s)	1 Strong Buy rating(s)	2.57
Heatwurx	1 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

In the previous week, Skye Bioscience had 5 more articles in the media than Heatwurx. MarketBeat recorded 9 mentions for Skye Bioscience and 4 mentions for Heatwurx. Heatwurx's average media sentiment score of 1.00 beat Skye Bioscience's score of 0.70 indicating that Heatwurx is being referred to more favorably in the news media.

Company	Overall Sentiment
Skye Bioscience	Positive
Heatwurx	Positive

Skye Bioscience has a beta of 3.03, suggesting that its share price is 203% more volatile than the broader market. Comparatively, Heatwurx has a beta of 1.01, suggesting that its share price is 1% more volatile than the broader market.

Skye Bioscience is trading at a lower price-to-earnings ratio than Heatwurx, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Skye Bioscience	N/A	N/A	-$55.92M	-$1.44	N/A
Heatwurx	N/A	N/A	-$13.56M	-$9.29	N/A

Skye Bioscience's return on equity of -217.27% beat Heatwurx's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Skye Bioscience	N/A	-217.27%	-162.39%
Heatwurx	N/A	-281.31%	-200.80%

Summary

Skye Bioscience beats Heatwurx on 10 of the 14 factors compared between the two stocks.

Get Heatwurx News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PCSA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PCSA vs. The Competition

Export

Metric	Heatwurx	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$7.29M	$3.04B	$6.46B	$12.34B
Dividend Yield	N/A	1.97%	2.76%	5.28%
P/E Ratio	-0.29	17.79	21.21	25.65
Price / Sales	N/A	336.21	554.38	86.31
Price / Cash	N/A	57.74	43.49	56.67
Price / Book	2.88	5.86	10.37	7.14
Net Income	-$13.56M	$74.99M	$3.57B	$335.98M
7 Day Performance	1.53%	3.11%	6.40%	4.15%
1 Month Performance	-11.07%	-3.05%	3.53%	2.54%
1 Year Performance	-55.78%	34.38%	34.04%	35.06%

Heatwurx Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PCSA Heatwurx	3.1769 of 5 stars	$2.65 flat	$25.00 +843.4%	-55.8%	$7.29M	N/A	N/A	20	Positive News Gap Down
BTAI BioXcel Therapeutics	2.1626 of 5 stars	$1.14 -5.8%	$11.00 +864.9%	-18.7%	$32.76M	$640K	N/A	90
SNTI Senti Biosciences	2.2625 of 5 stars	$1.01 -2.9%	$8.75 +766.3%	-69.2%	$32.39M	$20K	N/A	4	Negative News
NNVC NanoViricides	0.6389 of 5 stars	$1.48 -14.9%	N/A	-8.4%	$31.96M	N/A	N/A	20	Gap Down High Trading Volume
RNTX Rein Therapeutics	2.5521 of 5 stars	$1.05 -7.1%	$8.00 +661.9%	-49.8%	$31.68M	N/A	N/A	9	Gap Up

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PCSA) was last updated on 5/26/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Heatwurx (PCSA) Competitors

PCSA vs. BTAI, SNTI, NNVC, RNTX, and SKYE

How does Heatwurx compare to BioXcel Therapeutics?

Summary

How does Heatwurx compare to Senti Biosciences?

Summary

How does Heatwurx compare to NanoViricides?

Summary

How does Heatwurx compare to Rein Therapeutics?

Summary

How does Heatwurx compare to Skye Bioscience?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCSA vs. The Competition

Heatwurx Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Heatwurx (PCSA) Competitors

PCSA vs. BTAI, SNTI, NNVC, RNTX, and SKYE

How does Heatwurx compare to BioXcel Therapeutics?

Which has stronger earnings & valuation, PCSA or BTAI?

Is PCSA or BTAI more profitable?

Do institutionals & insiders hold more shares of PCSA or BTAI?

Do analysts rate PCSA or BTAI?

Which has more risk and volatility, PCSA or BTAI?

Does the media refer more to PCSA or BTAI?

Summary

How does Heatwurx compare to Senti Biosciences?

Which has preferable valuation & earnings, SNTI or PCSA?

Do insiders & institutionals believe in SNTI or PCSA?

Does the media prefer SNTI or PCSA?

Do analysts rate SNTI or PCSA?

Which has more volatility and risk, SNTI or PCSA?

Is SNTI or PCSA more profitable?

Summary

How does Heatwurx compare to NanoViricides?

Does the media prefer NNVC or PCSA?

Which has stronger valuation & earnings, NNVC or PCSA?

Is NNVC or PCSA more profitable?

Which has more risk & volatility, NNVC or PCSA?

Do institutionals & insiders believe in NNVC or PCSA?

Do analysts prefer NNVC or PCSA?

Summary

How does Heatwurx compare to Rein Therapeutics?

Do institutionals and insiders hold more shares of RNTX or PCSA?

Does the media prefer RNTX or PCSA?

Do analysts recommend RNTX or PCSA?

Which has better earnings & valuation, RNTX or PCSA?

Which has more volatility and risk, RNTX or PCSA?

Is RNTX or PCSA more profitable?

Summary

How does Heatwurx compare to Skye Bioscience?

Do insiders and institutionals hold more shares of SKYE or PCSA?

Do analysts recommend SKYE or PCSA?

Does the media prefer SKYE or PCSA?

Which has more volatility & risk, SKYE or PCSA?

Which has higher valuation & earnings, SKYE or PCSA?

Is SKYE or PCSA more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PCSA vs. The Competition

Heatwurx Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools